Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 1484Neoplasms 1101Carcinoma, Non-Small-Cell Lung 918Prostatic Neoplasms 802Multiple Myeloma 586Colorectal Neoplasms 535Leukemia, Myeloid, Acute 505Lung Neoplasms 489Lymphoma 455Melanoma 454Neoplasm Metastasis 451Lymphoma, Non-Hodgkin 416Leukemia 409Leukemia, Lymphocytic, Chronic, B-Cell 366Ovarian Neoplasms 357Pancreatic Neoplasms 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 334Recurrence 315Head and Neck Neoplasms 298Lymphoma, Follicular 297Myelodysplastic Syndromes 282Carcinoma, Renal Cell 272Glioblastoma 266Brain Neoplasms 265Hodgkin Disease 260Lymphoma, Large B-Cell, Diffuse 255Carcinoma, Hepatocellular 241Lymphoma, Mantle-Cell 219Squamous Cell Carcinoma of Head and Neck 214Stomach Neoplasms 210

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Perivascular Epithelioid Cell Neoplasms × Clear all
NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Sarcoma Oncology Research Center, LLC

Phase 1/2 Completed
34 enrolled 14 charts
DermatologicGastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chordoma, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Sarcoma, Ewing, Colorectal Neoplasms, Desmoid Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02494570 2023-04-07

AMPECT

Aadi Bioscience, Inc.

Phase 2 Completed
34 enrolled 15 charts 1 FDA

Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡